123I‐metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders
Identifieur interne : 000A47 ( Istex/Corpus ); précédent : 000A46; suivant : 000A48123I‐metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders
Auteurs : Olivier Rascol ; Ludwig ScheloskySource :
- Movement Disorders [ 0885-3185 ] ; 2009.
English descriptors
- KwdEn :
Abstract
Autonomic dysfunction is common in Lewy body disorders (Parkinson's disease, Dementia with Lewy Bodies, Pure Autonomic Failure, and REM sleep disorder). The loss of post‐ganglionic myocardial sympathetic nerve fibers is a prominent feature of autonomic dysfunction in such disorders. 123I‐metaiodobenzylguanidine (MIBG) scintigraphy that visualizes catecholaminergic terminals in vivo is a biomarker used to detect cardiac sympathetic degeneration. Abnormal MIBG uptake has been consistently reported in Lewy body disorders. Some studies agree in the notion that increasing bradykinesia is related with an incremental cardiac sympathetic denervation, whereas tremor is not closely linked to cardiac denervation. “Atypical” parkinsonian syndromes, including Multiple System Atrophy, Progressive Supranuclear Palsy, and others, show modest reductions of cardial MIBG uptake. MIBG scintigraphy is moderately sensitive and specific in differentiating Parkinson's disease from such syndromes. Conversely, its sensitivity and specificity might be better in cognitively impaired patients, helping differential diagnosis between Dementia with Lewy Bodies, and Alzheimer disease. Confounding factors (comorbidities, comedications) should be carefully controlled before analyzing MIBG scintigraphy. © 2009 Movement Disorder Society
Url:
DOI: 10.1002/mds.22499
Links to Exploration step
ISTEX:F0E4F24A5977047882DC9362028C31CB5E425B21Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">123I‐metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders</title><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>INSERM CIC‐P302 and UMR‐825, Departments of Clinical Pharmacology and Neurosciences, CHU and University UPS of Toulouse, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Schelosky, Ludwig" sort="Schelosky, Ludwig" uniqKey="Schelosky L" first="Ludwig" last="Schelosky">Ludwig Schelosky</name><affiliation><mods:affiliation>Neurologie und klinische Neurophysiologie, Kantonsspital Münsterlingen, Münsterlingen, Switzerland</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F0E4F24A5977047882DC9362028C31CB5E425B21</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/mds.22499</idno><idno type="url">https://api.istex.fr/document/F0E4F24A5977047882DC9362028C31CB5E425B21/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000A47</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">123I‐metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders</title><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>INSERM CIC‐P302 and UMR‐825, Departments of Clinical Pharmacology and Neurosciences, CHU and University UPS of Toulouse, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Schelosky, Ludwig" sort="Schelosky, Ludwig" uniqKey="Schelosky L" first="Ludwig" last="Schelosky">Ludwig Schelosky</name><affiliation><mods:affiliation>Neurologie und klinische Neurophysiologie, Kantonsspital Münsterlingen, Münsterlingen, Switzerland</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009">2009</date><biblScope unit="vol">24</biblScope><biblScope unit="issue">S2</biblScope><biblScope unit="page" from="S732">S732</biblScope><biblScope unit="page" to="S741">S741</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">F0E4F24A5977047882DC9362028C31CB5E425B21</idno><idno type="DOI">10.1002/mds.22499</idno><idno type="ArticleID">MDS22499</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>MIBG scintigraphy</term><term>MSA</term><term>Parkinson's disease</term><term>autonomic nervous system</term><term>cardiac sympathetic innervation</term><term>differential diagnosis</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Autonomic dysfunction is common in Lewy body disorders (Parkinson's disease, Dementia with Lewy Bodies, Pure Autonomic Failure, and REM sleep disorder). The loss of post‐ganglionic myocardial sympathetic nerve fibers is a prominent feature of autonomic dysfunction in such disorders. 123I‐metaiodobenzylguanidine (MIBG) scintigraphy that visualizes catecholaminergic terminals in vivo is a biomarker used to detect cardiac sympathetic degeneration. Abnormal MIBG uptake has been consistently reported in Lewy body disorders. Some studies agree in the notion that increasing bradykinesia is related with an incremental cardiac sympathetic denervation, whereas tremor is not closely linked to cardiac denervation. “Atypical” parkinsonian syndromes, including Multiple System Atrophy, Progressive Supranuclear Palsy, and others, show modest reductions of cardial MIBG uptake. MIBG scintigraphy is moderately sensitive and specific in differentiating Parkinson's disease from such syndromes. Conversely, its sensitivity and specificity might be better in cognitively impaired patients, helping differential diagnosis between Dementia with Lewy Bodies, and Alzheimer disease. Confounding factors (comorbidities, comedications) should be carefully controlled before analyzing MIBG scintigraphy. © 2009 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Olivier Rascol MD, PhD</name><affiliations><json:string>INSERM CIC‐P302 and UMR‐825, Departments of Clinical Pharmacology and Neurosciences, CHU and University UPS of Toulouse, Toulouse, France</json:string></affiliations></json:item><json:item><name>Ludwig Schelosky MD</name><affiliations><json:string>Neurologie und klinische Neurophysiologie, Kantonsspital Münsterlingen, Münsterlingen, Switzerland</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>MIBG scintigraphy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>autonomic nervous system</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>cardiac sympathetic innervation</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>differential diagnosis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>MSA</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Autonomic dysfunction is common in Lewy body disorders (Parkinson's disease, Dementia with Lewy Bodies, Pure Autonomic Failure, and REM sleep disorder). The loss of post‐ganglionic myocardial sympathetic nerve fibers is a prominent feature of autonomic dysfunction in such disorders. 123I‐metaiodobenzylguanidine (MIBG) scintigraphy that visualizes catecholaminergic terminals in vivo is a biomarker used to detect cardiac sympathetic degeneration. Abnormal MIBG uptake has been consistently reported in Lewy body disorders. Some studies agree in the notion that increasing bradykinesia is related with an incremental cardiac sympathetic denervation, whereas tremor is not closely linked to cardiac denervation. “Atypical” parkinsonian syndromes, including Multiple System Atrophy, Progressive Supranuclear Palsy, and others, show modest reductions of cardial MIBG uptake. MIBG scintigraphy is moderately sensitive and specific in differentiating Parkinson's disease from such syndromes. Conversely, its sensitivity and specificity might be better in cognitively impaired patients, helping differential diagnosis between Dementia with Lewy Bodies, and Alzheimer disease. Confounding factors (comorbidities, comedications) should be carefully controlled before analyzing MIBG scintigraphy. © 2009 Movement Disorder Society</abstract><qualityIndicators><score>7.004</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1321</abstractCharCount><pdfWordCount>5244</pdfWordCount><pdfCharCount>35595</pdfCharCount><pdfPageCount>10</pdfPageCount><abstractWordCount>167</abstractWordCount></qualityIndicators><title>123I‐metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders</title><genre><json:string>Serial article</json:string></genre><host><volume>24</volume><pages><total>10</total><last>S741</last><first>S732</first></pages><issn><json:string>0885-3185</json:string></issn><issue>S2</issue><subject><json:item><value>Research Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2009</publicationDate><copyrightDate>2009</copyrightDate><doi><json:string>10.1002/mds.22499</json:string></doi><id>F0E4F24A5977047882DC9362028C31CB5E425B21</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/F0E4F24A5977047882DC9362028C31CB5E425B21/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/F0E4F24A5977047882DC9362028C31CB5E425B21/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/F0E4F24A5977047882DC9362028C31CB5E425B21/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">123I‐metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2009</date></publicationStmt><notesStmt><note type="content">*Potential Conflict of Interest: L.S. has received honoraria from Boehringer Ingelheim in 2008.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">123I‐metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders</title><author><persName><forename type="first">Olivier</forename><surname>Rascol</surname><roleName type="degree">MD, PhD</roleName></persName><note type="correspondence"><p>Correspondence: Laboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine, 37 Allees J. Guesde, 31073 Toulouse Cedex, France</p></note><affiliation>INSERM CIC‐P302 and UMR‐825, Departments of Clinical Pharmacology and Neurosciences, CHU and University UPS of Toulouse, Toulouse, France</affiliation></author><author><persName><forename type="first">Ludwig</forename><surname>Schelosky</surname><roleName type="degree">MD</roleName></persName><affiliation>Neurologie und klinische Neurophysiologie, Kantonsspital Münsterlingen, Münsterlingen, Switzerland</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009"></date><biblScope unit="vol">24</biblScope><biblScope unit="issue">S2</biblScope><biblScope unit="page" from="S732">S732</biblScope><biblScope unit="page" to="S741">S741</biblScope></imprint></monogr><idno type="istex">F0E4F24A5977047882DC9362028C31CB5E425B21</idno><idno type="DOI">10.1002/mds.22499</idno><idno type="ArticleID">MDS22499</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2009</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Autonomic dysfunction is common in Lewy body disorders (Parkinson's disease, Dementia with Lewy Bodies, Pure Autonomic Failure, and REM sleep disorder). The loss of post‐ganglionic myocardial sympathetic nerve fibers is a prominent feature of autonomic dysfunction in such disorders. 123I‐metaiodobenzylguanidine (MIBG) scintigraphy that visualizes catecholaminergic terminals in vivo is a biomarker used to detect cardiac sympathetic degeneration. Abnormal MIBG uptake has been consistently reported in Lewy body disorders. Some studies agree in the notion that increasing bradykinesia is related with an incremental cardiac sympathetic denervation, whereas tremor is not closely linked to cardiac denervation. “Atypical” parkinsonian syndromes, including Multiple System Atrophy, Progressive Supranuclear Palsy, and others, show modest reductions of cardial MIBG uptake. MIBG scintigraphy is moderately sensitive and specific in differentiating Parkinson's disease from such syndromes. Conversely, its sensitivity and specificity might be better in cognitively impaired patients, helping differential diagnosis between Dementia with Lewy Bodies, and Alzheimer disease. Confounding factors (comorbidities, comedications) should be carefully controlled before analyzing MIBG scintigraphy. © 2009 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>MIBG scintigraphy</term></item><item><term>autonomic nervous system</term></item><item><term>cardiac sympathetic innervation</term></item><item><term>differential diagnosis</term></item><item><term>Parkinson's disease</term></item><item><term>MSA</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2008-10-29">Received</change><change when="2009-01-22">Registration</change><change when="2009">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/F0E4F24A5977047882DC9362028C31CB5E425B21/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="145"><doi origin="wiley" registered="yes">10.1002/mds.v24.2s</doi><numberingGroup><numbering type="journalVolume" number="24">24</numbering><numbering type="journalIssue">S2</numbering></numberingGroup><coverDate startDate="2009">2009</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="130" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.22499</doi><idGroup><id type="unit" value="MDS22499"></id></idGroup><countGroup><count type="pageTotal" number="10"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2009 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2008-10-29"></event><event type="manuscriptRevised" date="2008-12-08"></event><event type="manuscriptAccepted" date="2009-01-22"></event><event type="firstOnline" date="2009-10-28"></event><event type="publishedOnlineFinalForm" date="2009-10-28"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4 mode:FullText" date="2010-12-14"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">S732</numbering><numbering type="pageLast">S741</numbering></numberingGroup><correspondenceTo>Laboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine, 37 Allees J. Guesde, 31073 Toulouse Cedex, France</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS22499.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="6"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="79"></count><count type="wordTotal" number="5321"></count></countGroup><titleGroup><title type="main" xml:lang="en"><sup>123</sup>I‐metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders<link href="#fn3"></link></title><title type="short" xml:lang="en">MIBG Scintigraphy in Parkinson's Disease</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Olivier</givenNames><familyName>Rascol</familyName><degrees>MD, PhD</degrees></personName><contactDetails><email>rascol@cict.fr</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Ludwig</givenNames><familyName>Schelosky</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="FR" type="organization"><unparsedAffiliation>INSERM CIC‐P302 and UMR‐825, Departments of Clinical Pharmacology and Neurosciences, CHU and University UPS of Toulouse, Toulouse, France</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="CH" type="organization"><unparsedAffiliation>Neurologie und klinische Neurophysiologie, Kantonsspital Münsterlingen, Münsterlingen, Switzerland</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">MIBG scintigraphy</keyword><keyword xml:id="kwd2">autonomic nervous system</keyword><keyword xml:id="kwd3">cardiac sympathetic innervation</keyword><keyword xml:id="kwd4">differential diagnosis</keyword><keyword xml:id="kwd5">Parkinson's disease</keyword><keyword xml:id="kwd6">MSA</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Autonomic dysfunction is common in Lewy body disorders (Parkinson's disease, Dementia with Lewy Bodies, Pure Autonomic Failure, and REM sleep disorder). The loss of post‐ganglionic myocardial sympathetic nerve fibers is a prominent feature of autonomic dysfunction in such disorders. <sup>123</sup>I‐metaiodobenzylguanidine (MIBG) scintigraphy that visualizes catecholaminergic terminals in vivo is a biomarker used to detect cardiac sympathetic degeneration. Abnormal MIBG uptake has been consistently reported in Lewy body disorders. Some studies agree in the notion that increasing bradykinesia is related with an incremental cardiac sympathetic denervation, whereas tremor is not closely linked to cardiac denervation. “Atypical” parkinsonian syndromes, including Multiple System Atrophy, Progressive Supranuclear Palsy, and others, show modest reductions of cardial MIBG uptake. MIBG scintigraphy is moderately sensitive and specific in differentiating Parkinson's disease from such syndromes. Conversely, its sensitivity and specificity might be better in cognitively impaired patients, helping differential diagnosis between Dementia with Lewy Bodies, and Alzheimer disease. Confounding factors (comorbidities, comedications) should be carefully controlled before analyzing MIBG scintigraphy. © 2009 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn3"><p>Potential Conflict of Interest: L.S. has received honoraria from Boehringer Ingelheim in 2008.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 4-12-2015--><mods version="3.6"><titleInfo lang="en"><title>123I‐metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>MIBG Scintigraphy in Parkinson's Disease</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>I‐metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders</title></titleInfo><name type="personal"><namePart type="given">Olivier</namePart><namePart type="family">Rascol</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>INSERM CIC‐P302 and UMR‐825, Departments of Clinical Pharmacology and Neurosciences, CHU and University UPS of Toulouse, Toulouse, France</affiliation><description>Correspondence: Laboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine, 37 Allees J. Guesde, 31073 Toulouse Cedex, France</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ludwig</namePart><namePart type="family">Schelosky</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Neurologie und klinische Neurophysiologie, Kantonsspital Münsterlingen, Münsterlingen, Switzerland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2009</dateIssued><dateCaptured encoding="w3cdtf">2008-10-29</dateCaptured><dateValid encoding="w3cdtf">2009-01-22</dateValid><copyrightDate encoding="w3cdtf">2009</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">6</extent><extent unit="tables">1</extent><extent unit="references">79</extent><extent unit="words">5321</extent></physicalDescription><abstract lang="en">Autonomic dysfunction is common in Lewy body disorders (Parkinson's disease, Dementia with Lewy Bodies, Pure Autonomic Failure, and REM sleep disorder). The loss of post‐ganglionic myocardial sympathetic nerve fibers is a prominent feature of autonomic dysfunction in such disorders. 123I‐metaiodobenzylguanidine (MIBG) scintigraphy that visualizes catecholaminergic terminals in vivo is a biomarker used to detect cardiac sympathetic degeneration. Abnormal MIBG uptake has been consistently reported in Lewy body disorders. Some studies agree in the notion that increasing bradykinesia is related with an incremental cardiac sympathetic denervation, whereas tremor is not closely linked to cardiac denervation. “Atypical” parkinsonian syndromes, including Multiple System Atrophy, Progressive Supranuclear Palsy, and others, show modest reductions of cardial MIBG uptake. MIBG scintigraphy is moderately sensitive and specific in differentiating Parkinson's disease from such syndromes. Conversely, its sensitivity and specificity might be better in cognitively impaired patients, helping differential diagnosis between Dementia with Lewy Bodies, and Alzheimer disease. Confounding factors (comorbidities, comedications) should be carefully controlled before analyzing MIBG scintigraphy. © 2009 Movement Disorder Society</abstract><note type="content">*Potential Conflict of Interest: L.S. has received honoraria from Boehringer Ingelheim in 2008.</note><subject lang="en"><genre>Keywords</genre><topic>MIBG scintigraphy</topic><topic>autonomic nervous system</topic><topic>cardiac sympathetic innervation</topic><topic>differential diagnosis</topic><topic>Parkinson's disease</topic><topic>MSA</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><detail type="issue"><caption>no.</caption><number>S2</number></detail><extent unit="pages"><start>S732</start><end>S741</end><total>10</total></extent></part></relatedItem><identifier type="istex">F0E4F24A5977047882DC9362028C31CB5E425B21</identifier><identifier type="DOI">10.1002/mds.22499</identifier><identifier type="ArticleID">MDS22499</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2009 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A47 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000A47 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:F0E4F24A5977047882DC9362028C31CB5E425B21
|texte= 123I‐metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders
}}
| This area was generated with Dilib version V0.6.23. |  |